Bio-Techne Corp (TECH) versus Jaguar Animal Health (NASDAQ:JAGX) Head-To-Head Contrast
Bio-Techne Corp (NASDAQ: TECH) and Jaguar Animal Health (NASDAQ:JAGX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitabiliy, risk, earnings, dividends and institutional ownership.
This table compares Bio-Techne Corp and Jaguar Animal Health’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Jaguar Animal Health||-1,653.74%||-1,694.94%||-305.01%|
Risk and Volatility
Bio-Techne Corp has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500. Comparatively, Jaguar Animal Health has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500.
Valuation and Earnings
This table compares Bio-Techne Corp and Jaguar Animal Health’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Bio-Techne Corp||$541.19 million||7.99||$201.56 million||$1.86||62.25|
|Jaguar Animal Health||$925,786.00||9.20||-$12.08 million||N/A||N/A|
Bio-Techne Corp has higher revenue and earnings than Jaguar Animal Health.
This is a breakdown of current recommendations for Bio-Techne Corp and Jaguar Animal Health, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Jaguar Animal Health||0||0||2||0||3.00|
Bio-Techne Corp presently has a consensus price target of $121.25, indicating a potential upside of 4.72%. Jaguar Animal Health has a consensus price target of $2.00, indicating a potential upside of 238.98%. Given Jaguar Animal Health’s stronger consensus rating and higher probable upside, analysts clearly believe Jaguar Animal Health is more favorable than Bio-Techne Corp.
Insider and Institutional Ownership
96.9% of Bio-Techne Corp shares are held by institutional investors. Comparatively, 20.5% of Jaguar Animal Health shares are held by institutional investors. 2.7% of Bio-Techne Corp shares are held by insiders. Comparatively, 19.5% of Jaguar Animal Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Bio-Techne Corp pays an annual dividend of $1.28 per share and has a dividend yield of 1.1%. Jaguar Animal Health does not pay a dividend. Bio-Techne Corp pays out 68.8% of its earnings in the form of a dividend.
Bio-Techne Corp beats Jaguar Animal Health on 9 of the 14 factors compared between the two stocks.
Bio-Techne Corp Company Profile
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.
Jaguar Animal Health Company Profile
Jaguar Animal Health, Inc. is an animal health company. It is focused on developing and commercializing gastrointestinal products for companion and production animals, foals, and horses. Canalevia is its prescription drug product candidate, intended for treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree. It is developing a pipeline of prescription drug product candidates and non-prescription (non-drug) products to address needs in animal health. As of December 31, 2016, its pipeline includes prescription drug product candidates for nine indications across multiple species, and non-prescription products targeting seven species. Its product candidates include Canalevia, Species-specific formulations of crofelemer, Equilevia, Virend (topical), Species-specific formulations of NP-500, Neonorm Calf and Species-specific formulations of Neonorm.
Receive News & Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related companies with MarketBeat.com's FREE daily email newsletter.